Platelet glycoprotein IIb/IIIa inhibitors - Basic and clinical aspects

[11] Hanrath P, 1997, CIRCULATION, V96, P1445

[12] Inhibition of platelet-mediated clot retraction by integrin antagonists [J]. THROMBOSIS RESEARCH, 1998, 89 (06) : 271 - 279

[13] Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban - Results of a multicenter, placebo-controlled, randomized trial [J]. CIRCULATION, 1998, 98 (13) : 1268 - 1278

[14] DIFFERENTIAL INHIBITION OF PLATELET-AGGREGATION INDUCED BY ADENOSINE-DIPHOSPHATE OR A THROMBIN RECEPTOR-ACTIVATING PEPTIDE IN PATIENTS TREATED WITH BOLUS CHIMERIC 7E3 FAB - IMPLICATIONS FOR INHIBITION OF THE INTERNAL POOL OF GPIIB/IIIA RECEPTORS [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (07) : 1665 - 1671

[15] Increased platelet responsiveness following coronary stenting - Heparin as a possible aetiological factor in stent thrombosis [J]. EUROPEAN HEART JOURNAL, 1998, 19 (08) : 1239 - 1248

[16] Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade [J]. CIRCULATION, 1998, 97 (17) : 1680 - 1688

[17] Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802 [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (02) : 169 - 176

[18] ''Rescue'' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (07) : 1729 - 1734

[19] Distribution of ligand-occupied alpha(IIb)beta(3) in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6 [J]. BLOOD, 1996, 88 (03) : 887 - 899

[20] Nurden P, 1997, THROMB HAEMOSTASIS, V78, P1305

[11] Hanrath P, 1997, CIRCULATION, V96, P1445

[12] Inhibition of platelet-mediated clot retraction by integrin antagonists [J]. THROMBOSIS RESEARCH, 1998, 89 (06) : 271 - 279

[13] Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban - Results of a multicenter, placebo-controlled, randomized trial [J]. CIRCULATION, 1998, 98 (13) : 1268 - 1278

[14] DIFFERENTIAL INHIBITION OF PLATELET-AGGREGATION INDUCED BY ADENOSINE-DIPHOSPHATE OR A THROMBIN RECEPTOR-ACTIVATING PEPTIDE IN PATIENTS TREATED WITH BOLUS CHIMERIC 7E3 FAB - IMPLICATIONS FOR INHIBITION OF THE INTERNAL POOL OF GPIIB/IIIA RECEPTORS [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (07) : 1665 - 1671

[15] Increased platelet responsiveness following coronary stenting - Heparin as a possible aetiological factor in stent thrombosis [J]. EUROPEAN HEART JOURNAL, 1998, 19 (08) : 1239 - 1248

[16] Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade [J]. CIRCULATION, 1998, 97 (17) : 1680 - 1688

[17] Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802 [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (02) : 169 - 176

[18] ''Rescue'' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (07) : 1729 - 1734

[19] Distribution of ligand-occupied alpha(IIb)beta(3) in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6 [J]. BLOOD, 1996, 88 (03) : 887 - 899

[20] Nurden P, 1997, THROMB HAEMOSTASIS, V78, P1305